Iambic Therapeutics, which specialises in applying AI to drug discovery and development, has filed for an IPO on the Nasdaq, shortly after adding AbbVie to its roster of pharma pa ...
An adjuvanted, trivalent influenza vaccine developed by CSL Seqirus and recently approved in the UK, Aujemflu, will be deployed ahead of the 2027/28 flu season under an agreement with the government.
A consumer advocacy group has scrutinised some of the Most Favoured Nation (MFN) pricing deals the Trump administration has ...
Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience in a deal valued at $470 million. The $8-per-share deal will ...
Isomorphic Labs' chief executive, Sir Demis Hassabis, delivering his Nobel Prize lecture in 2024. Alphabet-backed start-up Isomorphic Labs has added to the lustre attached to its AI-powered drug ...
Zealand Pharma's CEO, Adam Steensberg. Shares in Zealand Pharma lost around a third of their value today, after it reported phase 2 data with Roche-partnered weight-loss therapy petrelintide. The sell ...
Shares in Abivax were tracking up this morning as a media report in France suggested a takeover by Eli Lilly – worth €15 billion ($17.5 billion) – could be on the cards. French newspaper La Lettre ...
The UK government has published a list of the best- and worst-performing NHS trusts in England for the first time, part of a drive to end the 'postcode lottery' of care. Health Secretary Wes Streeting ...
Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Roche has posted a mixed set of data from two clinical trials of its anti-IL-33/ST2 antibody astegolimab in chronic obstructive pulmonary disease (COPD), casting a shadow over the programme. On the ...
NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”. The ...
Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US. The company has received a complete response letter (CRL) from the FDA for a proposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results